Search
MVC-COV1901
go.drugbank.com/drugs/DB15854InvestigationalThe vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigationalFood and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081] … [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP.
Synonyms: under control of a human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, Replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteinsTideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Omapatrilat
go.drugbank.com/drugs/DB00886ExperimentalThe inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. … This drug from BMS was not approved by the FDA due to angioedema safety concerns.
Categories: Agents Acting on the Renin-Angiotensin SystemPefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Metabolic Side Effects of Drugs and SubstancesImlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft. … [A225836] High levels of anti-HLA antibodies also contribute to poor graft survival.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14397ApprovedThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeLevocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine was discovered at Janssen Pharmaceutica in 1979.
Categories: Histamine H1 Antagonists, Non-SedatingGoralatide
go.drugbank.com/drugs/DB20748ExperimentalGoralatide has a monoisotopic molecular weight of 487.23 Da.
Categories: Compounds used in a research, industrial, or household setting